Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Eva Ciruelos GilM VidalE Martínez de DueñasN Martínez-JáñezY FernándezJ A García-SáenzL MurilloF CarabantesA BelieraR FonsecaJ GaviláPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2017)
The safety profile in Spanish patients of the BALLET trial is consistent with the results obtained in the overall population of the trial, as well as in previous clinical trials.